糖尿病ケア機器と薬剤の市場規模、シェア、成長分析：タイプ別、流通チャネル別、最終用途別、地域別 - 産業予測 2025～2032年

糖尿病ケア機器と薬剤市場規模は2023年に301億8,000万米ドルと評価され、2024年の325億6,000万米ドルから2032年には598億3,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.9％で成長する見通しです。

国際糖尿病連合によると、約5億3,700万人の成人が罹患する世界の健康問題として急増している糖尿病患者にとって、インスリン調節による血糖値の管理は極めて重要です。糖尿病、特に2型糖尿病の有病率の増加は、特に中低所得国における肥満率の上昇、不健康な食生活、座りがちなライフスタイルに大きく起因しています。このような患者数の増加が、血糖値管理を簡素化する持続血糖モニターを含む糖尿病ケア機器の需要を大きく促進しています。特に2型糖尿病の診断件数の増加に伴い、ヘルスケアコストが上昇しているため、市場は成長する見込みです。市場セグメンテーションは、この重要なヘルスケアセグメントでより大きな市場シェアを獲得することを目指し、インスリン送達デバイスを強化するための技術革新への投資を増やしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

糖尿病ケア機器と薬剤市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• BGMデバイス
  • 自己監視デバイス
  • 血糖値測定器
  • テストストリップ
  • ランセット
  • 持続血糖測定装置
  • センサー
  • 送信機
  • 受信機
• インスリン投与装置
  • ポンプ
  • ペン
  • 注射器と針
  • ジェットインジェクター

糖尿病ケア機器と薬剤市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• 糖尿病クリニック/センター
• オンライン薬局
• その他

糖尿病ケア機器と薬剤市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• 病院
• 診断センター
• 在宅ケア

糖尿病ケア機器と薬剤市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novo Nordisk（Denmark）
• Medtronic（Ireland）
• Abbott Laboratories（United States）
• Johnson & Johnson（United States）
• Biocon（India）
• Eli Lilly and Company（United States）
• Roche（Switzerland）
• Bayer（Germany）
• Dexcom（United States）
• Insulet Corporation（United States）
• Tandem Diabetes Care（United States）
• Ascensia Diabetes Care（Switzerland）
• Terumo Corporation（Japan）
• Becton, Dickinson and Company（United States）
• AstraZeneca（United Kingdom）
• Pfizer（United States）
• Merck & Co.（United States）
• GlaxoSmithKline（United Kingdom）
• McKesson Corporation（United States）

結論と提言

Diabetes Care Devices and Drugs Market size was valued at USD 30.18 billion in 2023 and is poised to grow from USD 32.56 billion in 2024 to USD 59.83 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

The management of blood glucose levels through insulin regulation is critical for individuals with diabetes, a rapidly rising global health concern affecting approximately 537 million adults according to the International Diabetes Federation. The increasing prevalence of diabetes, particularly type 2, largely stems from rising obesity rates, unhealthy diets, and sedentary lifestyles, especially in low- and middle-income countries. This growing patient population significantly drives the demand for diabetes care devices, including continuous glucose monitors, which simplify glucose management. The market is poised for growth as healthcare costs escalate alongside the rising number of diagnoses, particularly for type 2 diabetes. Manufacturers are increasingly investing in technological innovations to enhance insulin delivery devices, aiming to capture larger market shares in this vital healthcare segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetes Care Devices And Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetes Care Devices And Drugs Market Segments Analysis

Global Diabetes Care Devices and Drugs Market is segmented by Type, Distribution Channel, End-use and region. Based on Type, the market is segmented into BGM Devices and Insulin Delivery Devices. Based on Distribution Channel, the market is segmented into Hospital pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies and Others. Based on End-use, the market is segmented into Hospitals, Diagnostic Centers and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetes Care Devices And Drugs Market

One of the primary catalysts for the expansion of the global diabetes care devices and drugs market is the continuous introduction of innovative products aimed at diabetes monitoring and treatment. A notable example is the research conducted by the Universidade de Lisboa in Portugal, which demonstrated in April 2020 that coating insulin-loaded nanoparticles with chitosan could significantly improve the oral delivery of insulin. Furthermore, the rising investments in research and development, along with collaborative efforts in the field, are expected to provide additional opportunities for market growth, reinforcing the overall advancement of diabetes management solutions.

Restraints in the Diabetes Care Devices And Drugs Market

The growth of the global diabetes care devices and drugs market may be hindered by several factors, including limited reimbursement options, stringent regulations, and increasing obesity rates in certain regions. Additionally, the lack of awareness surrounding diabetes diagnosis and treatment, particularly in emerging markets, poses a significant challenge to market expansion. These obstacles can lead to reduced accessibility and adoption of diabetes care solutions, further impeding the development of the market. Addressing these issues will be essential to enhance growth prospects and improve the overall effectiveness of diabetes management strategies worldwide.

Market Trends of the Diabetes Care Devices And Drugs Market

The Diabetes Care Devices and Drugs market has experienced a notable positive trend, catalyzed by the COVID-19 pandemic, which heightened awareness and concern over diabetes management among patients. With diabetics facing elevated risks from the virus, the demand for advanced monitoring devices surged as individuals sought to manage their condition more effectively from home. This shift resulted in a significant increase in the adoption of home-based diabetes care solutions, driven by a desire to minimize hospital visits. As a result, the market has seen innovations in drug formulations and device technology aimed at improving blood glucose monitoring and overall diabetes management, indicating a sustained growth trajectory in response to evolving patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Diabetes Care Devices and Drugs Market Size by Type & CAGR (2025-2032)

• Market Overview
• BGM Devices
  • Self-Monitoring Devices
  • Blood Glucose Meters
  • Testing Strips
  • Lancets
  • Continuous Glucose Monitoring Devices
  • Sensors
  • Transmitters
  • Receiver
• Insulin Delivery Devices
  • Pumps
  • Pens
  • Syringes and Needles
  • Jet Injectors

Global Diabetes Care Devices and Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital pharmacies
• Retail Pharmacies
• Diabetes Clinics/Centers
• Online Pharmacies
• Others

Global Diabetes Care Devices and Drugs Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Centers
• Homecare

Global Diabetes Care Devices and Drugs Market Size & CAGR (2025-2032)

• North America (Type, Distribution Channel, End-use)
  • US
  • Canada
• Europe (Type, Distribution Channel, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Distribution Channel, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Distribution Channel, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Distribution Channel, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascensia Diabetes Care (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McKesson Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations